Life Biosciences has raised $80 million in a Series D round to fund the clinical development of its lead therapy, ER-100, and expand its broader platform targeting the biology of aging.
The capital will support a Phase 1 human trial already underway in patients with optic neuropathies, including glaucoma and non-arteritic anterior ischemic optic neuropathy.…
